Evaluating the effectiveness of PCSK9 inhibitors for cholesterol management in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses how well patients adhere to and persist with treatment using PCSK9 inhibitors, specifically Repatha and Praluent, in a real-life setting across various locations in Italy. The study aims to gather data on the efficacy of these treatments in managing hypercholesterolemia among the Italian population. By monitoring patient outcomes and treatment adherence, the study seeks to provide insights into the real-world effectiveness of these medications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients under PCSK9 inhibitor treatment.

Exclusion Criteria:

* Age \< 18 years o \> 80 years;
* Patients who refuse to participate and to sign informed consent.

Where it's running

• Ospedali dell'Ovest Vicentino
  Arzignano, Italy Recruiting
• University of Bari Aldo Moro
  Bari, Italy Recruiting
• University of Campania Luigi Vanvitelli
  Caserta, Italy Recruiting
• University Magna Graecia of Catanzaro
  Catanzaro, Italy Recruiting
• Presidio Ospedaliero Maria SS Addolorata
  Eboli, Italy Recruiting
• Policlinico Riuniti Foggia
  Foggia, Italy Recruiting

Study contacts

• Study coordinator: Pasquale Perrone Filardi, MD
• Email: fpperron@unina.it
• Phone: +390817462224

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Enlicitide (MK-0616) for adults with high cholesterol in India

  This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.

  Recruiting at 2 sites Phase 3 Merck Sharp & Dohme LLC · Belagavi, Karnataka and 1 other locations · NCT07821944

• Pemafibrate in people with high cholesterol not fully controlled by statins

  This study tests whether taking Pemafibrate at 0.2 mg or 0.4 mg daily for 12 weeks helps people with high cholesterol who still don’t respond well to statins, compared with a placebo.

  Recruiting at 10 sites Phase 4 Kowa Company, Ltd. · Hokkaido and 9 other locations · NCT07634484

• Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance

  This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.

  Recruiting Phase 4 University Medical Centre Ljubljana · Ljubljana · NCT07581808

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Corn oil versus avocado oil effects on cardiometabolic risk factors

  This trial will test whether following controlled diets containing either corn oil or avocado oil for 21 days changes cardiometabolic risk factors in adults with mildly to moderately high non‑HDL cholesterol.

  Recruiting Midwest Center for Metabolic and Cardiovascular Research · Addison, Illinois · NCT07514663

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.